Basic Information
RNALocate ID: | RLID:11001776 |
RNA Symbol: | hsa-miR-142-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-142-5p |
RNA ID: | miRBase:MIMAT0000433 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 27278097 |
Tissue/Cell Line: | Bronchoalveolar lavage fluid|Pooled sera |
Method: | miRNA array|qRT-PCR |
MiRNAs involved in endothelial activation miR-92a and inflammation miR-182, AMR miR-142-5p, and Th 17 activation miR-155 in exosomes derived from sera and BAL fluid from BOS LTxRs compared with stable LTxRs. (y axis: relative fold change; x axis: sample source). Originally published in Am J Transplant. Gunasekaran M, et al, 2017. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | qRT-PCR demonstrated significant upregulation of miR-92a (p<0.013) and miR-182 (p<0.020) in AR LTxRs compared with stable LTxRs, and significant upregulation of miR-92a (p<0.041), miR-182 (p<0.012), miR-142-5p (p<0.015), and miR-155 (p<0.002) in BOS LTxRs compared with stable LTxRs. Similarly, exosomes derived from BAL fluid showed significant upregulation of miR-92a (p<0.014) and miR-182 (p<0.026) in AR LTxRs compared with stable LTxRs, and significant upregulation of miR-92a (p<0.024), miR-182 (p<0.026), miR-142-5p (p<0.026), and miR-155 (p<0.008) in BOS LTxRs compared with stable LTxRs (Figure 7). This shows that miRNAs involved in inflammation and endothelial activation were significantly increased in both AR and BOS LTxRs, and that the IL17 pathway was activated in BOS LTxRs. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001785 | Endoplasmic reticulum membrane | Cortical tissue | 32451872 |
RLID:11001777 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001778 | Exosome | Renal cancer cells | 21670082 |
RLID:11001779 | Exosome | HCC cell line (Hep3B|HepG2|PLC/PRF/5) | 21721029 |
RLID:11001780 | Exosome | Breast milk | 22211110 |
RLID:11001781 | Exosome | Brain tissue | 23382797 |
RLID:11001782 | Exosome | Plasma | 23663360 |
RLID:11001783 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001785 | Microvesicle | Liver resident stem cells | 20668554 |
RLID:11001786 | Microvesicle | Plasma | 23077538 |
RLID-D:11000083 | Exosome | Blood|B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Lymphoma tissue|Mast cells | |
RLID-D:11000361 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-142-5p | Mantle cell lymphoma | MNDR-E-MI-14022 |
MNDR | hsa-miR-142-5p | Splenic marginal zone lymphoma | MNDR-E-MI-14023 |
MNDR | hsa-miR-142-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-14024 |
MNDR | hsa-miR-142-5p | Oral squamous cell carcinoma | MNDR-E-MI-14025 |
MNDR | hsa-miR-142-5p | Medulloblastoma | MNDR-E-MI-14026 |
MNDR | hsa-miR-142-5p | Malt lymphoma | MNDR-E-MI-14027 |
MNDR | hsa-miR-142-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-14028 |
MNDR | hsa-miR-142-5p | Lymphoma | MNDR-E-MI-14029 |
MNDR | hsa-miR-142-5p | Lymphoma non-hodgkin | MNDR-E-MI-14030 |
MNDR | hsa-miR-142-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-14031 |
MNDR | hsa-miR-142-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-14032 |
MNDR | hsa-miR-142-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-14033 |
MNDR | hsa-miR-142-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-14034 |
MNDR | hsa-miR-142-5p | Her2-receptor positive breast cancer | MNDR-E-MI-14035 |
MNDR | hsa-miR-142-5p | Breast cancer luminal | MNDR-E-MI-14036 |
MNDR | hsa-miR-142-5p | Lupus nephritis | MNDR-E-MI-14037 |
MNDR | hsa-miR-142-5p | Dermatomyositis | MNDR-E-MI-14038 |
MNDR | hsa-miR-142-5p | Prostate cancer | MNDR-E-MI-14039 |
MNDR | hsa-miR-142-5p | Hirschsprung disease | MNDR-E-MI-14040 |
MNDR | hsa-miR-142-5p | Gastric lymphoma | MNDR-E-MI-14041 |
MNDR | hsa-miR-142-5p | Alzheimer disease | MNDR-E-MI-14042 |
MNDR | hsa-miR-142-5p | Intracranial aneurysm | MNDR-E-MI-14043 |
MNDR | hsa-miR-142-5p | Esophageal carcinoma | MNDR-E-MI-14044 |
MNDR | hsa-miR-142-5p | Head and neck cancer | MNDR-E-MI-14045 |
MNDR | hsa-miR-142-5p | Malaria | MNDR-E-MI-14046 |
MNDR | hsa-miR-142-5p | Leukemia | MNDR-E-MI-14047 |
MNDR | hsa-miR-142-5p | Huntington disease | MNDR-E-MI-14048 |
MNDR | hsa-miR-142-5p | Chorea | MNDR-E-MI-14049 |
MNDR | hsa-miR-142-5p | Cardiovascular disease | MNDR-E-MI-14050 |
MNDR | hsa-miR-142-5p | Lung cancer | MNDR-E-MI-14051 |
MNDR | hsa-miR-142-5p | Parkinson disease | MNDR-E-MI-14052 |
MNDR | hsa-miR-142-5p | Machado-joseph disease | MNDR-E-MI-14053 |
MNDR | hsa-miR-142-5p | Basal-like breast cancer | MNDR-E-MI-14054 |
MNDR | hsa-miR-142-5p | Pancreatic cancer | MNDR-E-MI-14055 |
MNDR | hsa-miR-142-5p | Melanoma | MNDR-E-MI-14056 |
MNDR | hsa-miR-142-5p | Rectum adenocarcinoma | MNDR-E-MI-14057 |
MNDR | hsa-miR-142-5p | Nephroblastoma | MNDR-E-MI-14058 |
MNDR | hsa-miR-142-5p | Colon cancer | MNDR-E-MI-14059 |
MNDR | hsa-miR-142-5p | Colon adenocarcinoma | MNDR-E-MI-14060 |
MNDR | hsa-miR-142-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-14061 |
MNDR | hsa-miR-142-5p | Familial ovarian cancer | MNDR-E-MI-14062 |
MNDR | hsa-miR-142-5p | Carcinoma ductal breast | MNDR-E-MI-14063 |
MNDR | hsa-miR-142-5p | Glioblastoma | MNDR-E-MI-14064 |
MNDR | hsa-miR-142-5p | Malignant glioma | MNDR-E-MI-14065 |
MNDR | hsa-miR-142-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-14066 |
MNDR | hsa-miR-142-5p | Osteosarcoma | MNDR-E-MI-14067 |
MNDR | hsa-miR-142-5p | Inclusion body myositis | MNDR-E-MI-14068 |
MNDR | hsa-miR-142-5p | Breast carcinoma | MNDR-E-MI-14069 |
MNDR | hsa-miR-142-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-14070 |
MNDR | hsa-miR-142-5p | Meningioma | MNDR-E-MI-14071 |
MNDR | hsa-miR-142-5p | Uterine cancer | MNDR-E-MI-14072 |
MNDR | hsa-miR-142-5p | Gastric adenocarcinoma | MNDR-E-MI-14073 |
MNDR | hsa-miR-142-5p | Cervical squamous cell carcinoma | MNDR-E-MI-14074 |
MNDR | hsa-miR-142-5p | Lung squamous cell carcinoma | MNDR-E-MI-14075 |
MNDR | hsa-miR-142-5p | Non-small cell lung cancer | MNDR-E-MI-14076 |
MNDR | hsa-miR-142-5p | Lung adenocarcinoma | MNDR-E-MI-14077 |
MNDR | hsa-miR-142-5p | Adrenocortical carcinoma | MNDR-E-MI-14078 |
MNDR | hsa-miR-142-5p | Thyroid carcinoma | MNDR-E-MI-14079 |
MNDR | hsa-miR-142-5p | Pancreatic adenocarcinoma | MNDR-E-MI-14080 |
MNDR | hsa-miR-142-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-14081 |
MNDR | hsa-miR-142-5p | Carcinoma renal cell | MNDR-E-MI-14082 |
MNDR | hsa-miR-142-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-14083 |
MNDR | hsa-miR-142-5p | Clear cell renal cell cancer | MNDR-E-MI-14084 |
MNDR | hsa-miR-142-5p | Cholangiocarcinoma | MNDR-E-MI-14085 |
MNDR | hsa-miR-142-5p | Esophageal cancer | MNDR-E-MI-14086 |
MNDR | hsa-miR-142-5p | Lung small cell carcinoma | MNDR-E-MI-14087 |
MNDR | hsa-miR-142-5p | Testicular germ cell cancer | MNDR-E-MI-14088 |
MNDR | hsa-miR-142-5p | Kidney diseases | MNDR-E-MI-14089 |
MNDR | hsa-miR-142-5p | Breast invasive carcinoma | MNDR-E-MI-14090 |
MNDR | hsa-miR-142-5p | Hepatocellular carcinoma | MNDR-E-MI-14091 |
MNDR | hsa-miR-142-5p | Familiar ovarian carcinoma | MNDR-E-MI-14092 |
MNDR | hsa-miR-142-5p | B-cell lymphoma | MNDR-E-MI-14093 |
MNDR | hsa-miR-142-5p | Rheumatoid arthritis | MNDR-E-MI-14094 |
MNDR | hsa-miR-142-5p | T-cell leukemia | MNDR-E-MI-14095 |
MNDR | hsa-miR-142-5p | Retinoblastoma | MNDR-E-MI-14096 |
MNDR | hsa-miR-142-5p | Barrett's adenocarcinoma | MNDR-E-MI-14097 |
MNDR | hsa-miR-142-5p | Chronic fatigue syndrome | MNDR-E-MI-14098 |
MNDR | hsa-miR-142-5p | Hodgkin lymphoma | MNDR-E-MI-14099 |
MNDR | hsa-miR-142-5p | Ulcerative colitis | MNDR-E-MI-14100 |
MNDR | hsa-miR-142-5p | Burkitt lymphoma | MNDR-E-MI-14101 |
MNDR | hsa-miR-142-5p | Dementia vascular | MNDR-E-MI-14102 |
MNDR | hsa-miR-142-5p | Tonsil cancer | MNDR-E-MI-14103 |
MNDR | hsa-miR-142-5p | Neuromyelitis optica | MNDR-E-MI-14104 |
MNDR | hsa-miR-142-5p | Skin cutaneous melanoma | MNDR-E-MI-14105 |
MNDR | hsa-miR-142-5p | Skin melanoma | MNDR-E-MI-14106 |
MNDR | hsa-miR-142-5p | Acute myeloid leukemia | MNDR-E-MI-14107 |
MNDR | hsa-miR-142-5p | Colorectal cancer | MNDR-E-MI-14108 |
MNDR | hsa-miR-142-5p | Nasopharynx carcinoma | MNDR-E-MI-14109 |
MNDR | hsa-miR-142-5p | Multiple myeloma | MNDR-E-MI-14110 |
MNDR | hsa-miR-142-5p | Fever | MNDR-E-MI-14111 |
MNDR | hsa-miR-142-5p | Cardiac hypertrophy | MNDR-E-MI-14112 |
MNDR | hsa-miR-142-5p | Nasopharyngeal cancer | MNDR-E-MI-14113 |
MNDR | hsa-miR-142-5p | Aids dementia complex | MNDR-E-MI-14114 |
MNDR | hsa-miR-142-5p | Stroke lacunar | MNDR-E-MI-14115 |
MNDR | hsa-miR-142-5p | Barrett's carcinogenesis | MNDR-E-MI-14116 |
MNDR | hsa-miR-142-5p | Breast cancer her3+ negative | MNDR-E-MI-14117 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AGER | Homo sapiens | RR00054545 |
TOP